Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097)
Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097)
This study is being conducted to demonstrate that aprepitant (MK-0869) prevents nausea and
 vomiting caused by emetogenic cancer chemotherapy in adolescent participants. Participants
 treated with emetogenic cancer chemotherapies that include either cisplatin,
 cyclophosphamide, or carboplatin, or participants who experienced nausea and/or vomiting when
 treated with a previously administered chemotherapy regimen that is planned to be repeated
 will be enrolled in this study. In the double-blind Part 1 of this study, enrolled
 participants will be randomized to receive either aprepitant or standard therapy. In Part 2
 of this study, enrolled participants will receive open-label aprepitant.
The duration of treatment is the first 4 days of one 28-day cycle (Cycle 1). Participants who
 successfully complete Cycle 1 may be eligible to participate for 9 subsequent optional,
 open-label, 28-day cycles.
Inclusion Criteria:

 -  Cycle 1: Participant is to be treated with an emetogenic chemotherapy regimen that
 includes either cisplatin, cyclophosphamide, or carboplatin, for a documented
 malignancy. OR Participant did not tolerate a previously administered chemotherapy
 regimen, for a documented malignancy, secondary to nausea and/or vomiting that is
 planned to be repeated.

 -  Cycle 1: Participant has Karnofsky score ≥60

 -  Cycle 1: Participant has a predicted life expectancy of ≥3 months

 Exclusion Criteria:

 -  Cycle 1: Participant will receive stem cell rescue therapy in conjunction with course
 of chemotherapy.